BRPI0416085A - álcoois de nitrofenil mostarda e nitrofenilaziridina e seus fosfatos correspondentes e seu uso como agentes citotóxicos alvo-dirigidos - Google Patents
álcoois de nitrofenil mostarda e nitrofenilaziridina e seus fosfatos correspondentes e seu uso como agentes citotóxicos alvo-dirigidosInfo
- Publication number
- BRPI0416085A BRPI0416085A BRPI0416085-1A BRPI0416085A BRPI0416085A BR PI0416085 A BRPI0416085 A BR PI0416085A BR PI0416085 A BRPI0416085 A BR PI0416085A BR PI0416085 A BRPI0416085 A BR PI0416085A
- Authority
- BR
- Brazil
- Prior art keywords
- cytotoxic agents
- corresponding phosphates
- target
- nitrophenylaziridine
- alcohols
- Prior art date
Links
- -1 nitrophenyl mustard Chemical compound 0.000 title abstract 5
- 229910019142 PO4 Inorganic materials 0.000 title abstract 3
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 3
- 239000002254 cytotoxic agent Substances 0.000 title abstract 3
- 231100000599 cytotoxic agent Toxicity 0.000 title abstract 3
- 235000021317 phosphate Nutrition 0.000 title abstract 3
- 150000003013 phosphoric acid derivatives Chemical class 0.000 title abstract 3
- 241000219198 Brassica Species 0.000 title abstract 2
- 235000003351 Brassica cretica Nutrition 0.000 title abstract 2
- 235000003343 Brassica rupestris Nutrition 0.000 title abstract 2
- 235000010460 mustard Nutrition 0.000 title abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 abstract 2
- 206010021143 Hypoxia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001146 hypoxic effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
- C07C309/66—Methanesulfonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
- C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
- C07D203/14—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom with carbocyclic rings directly attached to the ring nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ529249A NZ529249A (en) | 2003-10-31 | 2003-10-31 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic |
| NZ53561804 | 2004-09-28 | ||
| PCT/NZ2004/000275 WO2005042471A1 (en) | 2003-10-31 | 2004-10-29 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0416085A true BRPI0416085A (pt) | 2007-01-02 |
Family
ID=34555019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0416085-1A BRPI0416085A (pt) | 2003-10-31 | 2004-10-29 | álcoois de nitrofenil mostarda e nitrofenilaziridina e seus fosfatos correspondentes e seu uso como agentes citotóxicos alvo-dirigidos |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7629332B2 (https=) |
| EP (1) | EP1680394A4 (https=) |
| JP (1) | JP4760712B2 (https=) |
| KR (1) | KR101167335B1 (https=) |
| AU (1) | AU2004285831B2 (https=) |
| BR (1) | BRPI0416085A (https=) |
| CA (1) | CA2544335A1 (https=) |
| IL (1) | IL175000A0 (https=) |
| RU (1) | RU2372324C2 (https=) |
| WO (1) | WO2005042471A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004285831B2 (en) * | 2003-10-31 | 2011-09-15 | Auckland Uniservices Limited | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents |
| NZ549659A (en) * | 2006-09-04 | 2008-12-24 | Auckland Uniservices Ltd | Processes of preparing asymmetric dinitrobenzamide mustard compounds, intermediate compounds useful therein and products obtained therefrom |
| WO2008033041A1 (en) * | 2006-09-11 | 2008-03-20 | Auckland Uniservices Limited | Cancer treatment |
| WO2008033039A1 (en) * | 2006-09-11 | 2008-03-20 | Adam Vorn Patterson | Cancer treatment |
| NZ549831A (en) * | 2006-09-11 | 2009-03-31 | Auckland Uniservices Ltd | Combination of docetaxel and a nitrophenyl phosphate derivative for the treatment of cancer |
| ES2884044T3 (es) | 2006-12-26 | 2021-12-10 | Immunogenesis Inc | Profármaco alquilante de fosforamidato para el tratamiento del cáncer |
| US8309554B2 (en) * | 2008-05-15 | 2012-11-13 | Threshold Pharmaceuticals | Hypoxia activated drugs of nitrogen mustard alkylators |
| WO2010044685A1 (en) * | 2008-10-17 | 2010-04-22 | Auckland Uniservices Limited | Nitrophenyl mustard alcohols, their corresponding phosphates and their use as targeted cytotoxic agents |
| EP2350664B1 (en) | 2008-10-21 | 2021-05-19 | ImmunoGenesis, Inc. | Treatment of cancer using the hypoxia activated prodrug th-302 in combination with docetaxel or pemetrexed |
| CN101723932B (zh) * | 2008-10-31 | 2013-11-20 | 北京以岭生物工程技术有限公司 | 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途 |
| ES2877629T3 (es) | 2010-07-12 | 2021-11-17 | Immunogenesis Inc | Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer |
| EP2593796A4 (en) | 2010-07-16 | 2016-07-27 | Auckland Uniservices Ltd | BACTERIAL NITROREDUCTASE ENZYMES AND METHOD THEREFOR |
| CN104039328B (zh) * | 2011-11-11 | 2018-10-09 | 米伦纽姆医药公司 | 对蛋白酶体抑制剂的反应的生物标记 |
| EP2793882A4 (en) | 2011-12-22 | 2015-04-29 | Threshold Pharmaceuticals Inc | ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER |
| EP2793871A4 (en) * | 2011-12-23 | 2015-07-22 | Auckland Uniservices Ltd | COMPOUNDS AND METHODS FOR SELECTIVE IMAGING AND / OR ABLATION |
| US10202408B2 (en) | 2012-08-23 | 2019-02-12 | Health Innovation Ventures B.V. | Prodrugs and methods of use thereof |
| EP2888227B1 (en) * | 2012-08-23 | 2020-07-29 | Convert Pharmaceuticals SA | Novel prodrugs and methods of use thereof |
| WO2014062856A1 (en) | 2012-10-16 | 2014-04-24 | Halozyme, Inc. | Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods |
| JP2016528217A (ja) | 2013-07-26 | 2016-09-15 | スレッショルド ファーマシューティカルズ，インコーポレイテッド | 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療 |
| JP7327900B2 (ja) | 2015-06-24 | 2023-08-16 | スレッシュホールド ファーマシューティカルズ， インコーポレイテッド | アジリジン含有ｄｎａアルキル化剤 |
| US10348685B2 (en) * | 2016-04-29 | 2019-07-09 | Nicira, Inc. | Priority allocation for distributed service rules |
| CN108571241B (zh) * | 2017-03-14 | 2021-08-17 | 福特环球技术公司 | 用于推按式闩锁类型车辆抽屉的惯性锁系统 |
| WO2019125184A1 (en) | 2017-12-19 | 2019-06-27 | Auckland Uniservices Limited | Use of biomarker in cancer therapy |
| EP3774743B1 (en) * | 2018-03-29 | 2023-11-22 | Achilles Medical Limited | Prodrug compounds activated by akr1c3 and their use for treating hyperproliferative disorders |
| JP7541512B2 (ja) * | 2018-05-30 | 2024-08-28 | コンバート ファーマシューティカルズ エス．エー． | プロドラッグおよびその医学的使用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ240785A (en) * | 1991-11-28 | 1995-08-28 | Cancer Res Campaign Tech | Substituted nitro aniline derivatives and medicaments |
| GB9819472D0 (en) * | 1998-09-07 | 1998-10-28 | Cancer Soc Auckland Div Nz Inc | Novel nitrophenylaziridine compounds and their use as prodrugs |
| CA2460345A1 (en) * | 2001-09-13 | 2003-03-20 | Synta Pharmaceuticals Corp. | 2-aroylimidazole compounds for treating cancer |
| NZ521851A (en) * | 2002-10-08 | 2005-02-25 | Auckland Uniservices Ltd | Nitroaniline-based unsymmetrical mustard alkylating agents for gene dependent enzyme prodrug therapy |
| AU2004285831B2 (en) * | 2003-10-31 | 2011-09-15 | Auckland Uniservices Limited | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents |
-
2004
- 2004-10-29 AU AU2004285831A patent/AU2004285831B2/en not_active Ceased
- 2004-10-29 US US10/577,078 patent/US7629332B2/en not_active Expired - Fee Related
- 2004-10-29 RU RU2006118785/04A patent/RU2372324C2/ru not_active IP Right Cessation
- 2004-10-29 EP EP04817434A patent/EP1680394A4/en not_active Withdrawn
- 2004-10-29 JP JP2006537921A patent/JP4760712B2/ja not_active Expired - Fee Related
- 2004-10-29 KR KR1020067010566A patent/KR101167335B1/ko not_active Expired - Fee Related
- 2004-10-29 WO PCT/NZ2004/000275 patent/WO2005042471A1/en not_active Ceased
- 2004-10-29 BR BRPI0416085-1A patent/BRPI0416085A/pt not_active IP Right Cessation
- 2004-10-29 CA CA002544335A patent/CA2544335A1/en not_active Abandoned
-
2006
- 2006-04-11 IL IL175000A patent/IL175000A0/en unknown
-
2009
- 2009-08-11 US US12/461,419 patent/US20100010094A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1680394A1 (en) | 2006-07-19 |
| US20100010094A1 (en) | 2010-01-14 |
| IL175000A0 (en) | 2006-08-20 |
| US20070032455A1 (en) | 2007-02-08 |
| WO2005042471A1 (en) | 2005-05-12 |
| AU2004285831B2 (en) | 2011-09-15 |
| US7629332B2 (en) | 2009-12-08 |
| JP2007509928A (ja) | 2007-04-19 |
| EP1680394A4 (en) | 2006-10-11 |
| KR20070006677A (ko) | 2007-01-11 |
| AU2004285831A1 (en) | 2005-05-12 |
| JP4760712B2 (ja) | 2011-08-31 |
| RU2006118785A (ru) | 2007-12-10 |
| KR101167335B1 (ko) | 2012-07-19 |
| RU2372324C2 (ru) | 2009-11-10 |
| CA2544335A1 (en) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0416085A (pt) | álcoois de nitrofenil mostarda e nitrofenilaziridina e seus fosfatos correspondentes e seu uso como agentes citotóxicos alvo-dirigidos | |
| Yang et al. | Enzyme-mediated hydrolytic activation of prodrugs | |
| GB9415167D0 (en) | Improvements relating to cancer therapy | |
| IL158623A0 (en) | Subcellular targeting of therapeutic proteins | |
| Mishra et al. | Therapeutic potential of prodrugs towards targeted drug delivery | |
| AR032293A1 (es) | Estuche farmaceutico | |
| IL207446A0 (en) | Acid alpha-glucosidase and fragments thereof | |
| AU2001288025A1 (en) | Peptide conjugated anti-cancer prodrugs | |
| BR0206648A (pt) | Inserto de corte, e, ferramenta de corte | |
| WO2007044323A3 (en) | Fusion proteins for blood-brain barrier delivery | |
| TW200514252A (en) | Self-aligned planar double-gate process by self-aligned oxidation | |
| MA30322B1 (fr) | Promedicaments ameliores d'analogues de cc-1065 | |
| MX2007012817A (es) | Eliminacion de poblacion celular heterogenea o mezclada en tumores. | |
| TR199902731T2 (xx) | Kimyasal bile�ikler. | |
| WO2024073723A3 (en) | Anti-cd122 antibodies and uses thereof | |
| WO2004112717A3 (en) | Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof | |
| AR051765A1 (es) | Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas | |
| BRPI0606520A2 (pt) | tripeptìdeo e tetrapeptìdeo tioéteres | |
| WO2004053054A3 (en) | Nk cell receptor conjugates for treating malignancies | |
| NZ309171A (en) | use of apoptin as an antitumour agent which specifically kills tumour and not normal cells | |
| ATE187890T1 (de) | Ligandgerichtete enzyme-prodrug therapie | |
| DE69932261D1 (de) | P450 / acetaminophen gdept zur krebsbehandlung | |
| Blakey et al. | Antibody-directed enzyme prodrug therapy (ADEPT) for treatment of major solid tumour disease | |
| UA89363C2 (ru) | Нитрофенилипритные и нитрофенилазиридиновые спирты и их соответствующие фосфаты, и их применение как нацеленных цитотоксичных средств | |
| WO2022020473A3 (en) | Disruption of cd28-sialoside ligand complexes to enhance t cell activation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2278 DE 02/09/2014. |